Welcome to Roivant

Reinventing the discovery, development, and commercialization of new medicines

About Us

We develop transformative medicines and technologies by building agile, focused companies called Vants.

Our companies

Our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

We employ technology across discovery, development, and commercialization.

Woman Rubbing Her Shoulder


Leading innovation in medical dermatology



Advancing potentially transformative therapies for autoimmune diseases

Scientist in Lab


Delivering results through nucleic acids

Investor Update
video section decoration

Our CEO, Matt Gline, shares Roivant's progress and growth as VTAMA continues its positive impact on psoriasis patients, and Immunovant shares a new promising compound, IMVT-1402.

Our Science

Designing Better Molecules, Atom by Atom




We have built an end-to-end platform for heterobifunctional degrader discovery which we are expanding to other chemically-induced proximity applications. Learn more.


We’re expanding the druggable proteome and unlocking the next generation of high value small molecule therapeutics. Learn more.

Designing Best-in-Class Small Molecules

Our computation-first approach is used to design molecules that rapidly reach the desired TPP for disease areas where effective therapeutic solutions are lacking. Learn more.



Our discovery computational platform, QUAISAR (QUantum, AI, and Structure-Activity Relationships) is leveraged to gain critical project insights and desired properties for drug engineering.


Recent Publications

Rigorous Free Energy Simulations in Virtual Screening

Virtual high throughput screening (vHTS) in drug discovery is a power approach to identify hits: when applied successfully, it can be much faster and cheaper than experimental high-throughput screening approaches. However, mainstream vHTS tools have significant limitations: ligand-based methods depend on knowledge of existing chemical matter, while structure-based tools such as docking involve...

For Investors
For Investors

Learn more about our work

Sign up for our latest announcements and upcoming presentations


Advancing medicines that matter

View our broad and differentiated pipeline of investigational drugs.